Alteplase: profile and news

Nuvelo and Bayer HealthCare Begin SONOMA-3, Second Phase 3 Trial ...  Feb 27, 2006
...dose, respectively. By comparison, Cathflo(R)Activase(R) (alteplase) did not restore flow at either time point. Alfimeprase also ... - International News Service,

Nuvelo and Bayer begin second alfimeprase trial  Feb 28, 2006
...minutes after the first dose, respectively. By comparison, CathfloActivase (alteplase) did not restore flow at either time point. - Pharmaceutical Business Review

Nuvelo and Bayer HealthCare Begin SONOMA-3, Second Phase 3 Trial ...  Feb 27, 2006
...first dose, respectively. By comparison, Cathflo®Activase® (alteplase) did not restore flow at either time point. Alfimeprase also ... - Yahoo! News (press release)

ASA: ReoPro-Retavase Duo Promising as Late Reperfusion Stroke ...  Feb 20, 2006
...planned as a 72-patient trial of targeted thrombolytic therapies initiated after the three-hour window approved for treatment with Activase (alteplase [rt-PA ... - MedPage Today,

New England Journal of Medicine Publishes NXY-059 Study, The First ...  Feb 8, 2006
The incidence of symptomatic intracranial hemorrhage (ICH) in patients treated with NXY-059 and alteplase, a tissue plasminogen activator (rt-PA), was lower ... - Antara,

Analysis: AstraZ's stroke drug promising  Feb 8, 2006
The research team noted that among patients who also received alteplase, those receiving NXY-059 had a lower incidence of any hemorrhagic transformation and ... - United Press International

FibroGen Reports FG-4539, HIF-PH Inhibitor, is Neuroprotective and ...  Feb 17, 2006
The US Food and Drug Administration has approved tissue plasminogen activator, or tPA, (ie, Alteplase) to treat ischemic stroke. ... - Genetic Engineering News,

Thrombolytic Treatment Before Stenting Linked to Increased ...  Feb 14, 2006
There was increased mortality only in patients who were pre-treated with thrombolytics such as TNKase (tenecteplase) or Activase (alteplase). ... - MedPage Today,

Neuroprotective Agent Improves Outcome After Ischemic Stroke  Feb 9, 2006
...with placebo. The subset of patients who also received alteplase had a lower incidence of intracranial hemorrhage. "Neuroprotective ... - Medscape (subscription)

NXY-059 for Acute Ischemic Stroke  Feb 9, 2006
In a post hoc analysis of patients who also received alteplase, NXY-059 was associated with a lower incidence of any hemorrhagic transformation (P=0.001) and ... - New England Journal of Medicine (subscription),

NXY-059 for acute ischemic stroke  Feb 9, 2006
The incidence of symptomatic intracranial hemorrhage in patients treated with NXY-059 and Alteplase, a tissue plasminogen activator ( rt-PA ), was lower than ... - Xagena.it,